Procept Biorobotics stock hits 52-week low at 47.0 USD

Procept Biorobotics Corp stock has reached a new 52-week low, touching 47.0 USD. According to InvestingPro data, technical indicators suggest the stock is in oversold territory, while the company maintains a healthy balance sheet with more cash than debt and a strong current ratio of 8.95. This milestone reflects a significant downturn for the company, as its stock has experienced a 20.84% decline over the past year. Despite the challenges, the company has achieved impressive revenue growth of 59.36% in the last twelve months. The drop to this 52-week low highlights the current market sentiment, though analyst targets suggest potential upside, with price targets ranging from $60 to $90. Investors are closely monitoring Procept Biorobotics’ performance, as the company navigates through this period. For deeper insights and additional ProTips, access the comprehensive Pro Research Report available on InvestingPro.

In other recent news, PROCEPT BioRobotics announced a significant leadership change, with Larry L. Wood set to become the new President and CEO effective September 2, 2025. This transition follows the retirement of Dr. Reza Zadno, who will step down after five years in the role. The company also reported a notable 48% growth in revenue, highlighting its strong financial performance. Despite the proposed Medicare cuts impacting physician fees for its Aquablation therapy, BofA Securities has reiterated its Buy rating and maintains a price target of $84.00 for the company. Additionally, Truist Securities also upheld its Buy rating, pointing to positive utilization trends and a robust capital pipeline. Meanwhile, Oppenheimer initiated coverage with a Perform rating, reflecting a balanced risk-reward outlook. These developments underscore the company’s strategic shifts and financial health as it navigates the evolving healthcare landscape.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.